Plasma kinetics of apoC-III and apoE in normolipidemic and hypertriglyceridemic subjects

Journal of Lipid Research

Volumn 41, Issue 5, 2000, Pages 706-718

  Batal, Rami ^a   Tremblay, Michel ^a   Barrett, P Hugh R ^c   Jacques, Hélène ^a   Fredenrich, Alexandre ^a   Mamer, Orval ^b   Davignon, Jean ^a   Cohn, Jeffrey S ^a  

^a Hyperlipidemia and Atherosclerosis Research Group   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

ApoB; Atherosclerosis; Cholesterol; Metabolism; Remnants; Stable isotope; Triglyceride; Type III hyperlipoproteinemia

Indexed keywords

APOLIPOPROTEIN B100; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; HIGH DENSITY LIPOPROTEIN; LEUCINE; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HYPERLIPOPROTEINEMIA TYPE 3; HYPERTRIGLYCERIDEMIA; LIPID TRANSPORT; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; LIPOPROTEIN SYNTHESIS; MALE; PRIORITY JOURNAL;

ADULT; APOLIPOPROTEIN B-100; APOLIPOPROTEIN C-III; APOLIPOPROTEINS B; APOLIPOPROTEINS C; APOLIPOPROTEINS E; CASE-CONTROL STUDIES; FEMALE; HUMANS; HYPERTRIGLYCERIDEMIA; KINETICS; LIPOPROTEINS, HDL; LIPOPROTEINS, VLDL; MALE; MIDDLE AGED; REFERENCE VALUES; TRIGLYCERIDES;

EID: 0034102739     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Lenich, C., P. Brecher, S. Makrides, A. Chobanian, and V. I. Zannis. 1988. Apolipoprotein gene expression in the rabbit: abundance, size, and distribution of apolipoprotein mRNA species in different tissues. J. Lipid Res. 29: 755-764.
2. Schonfeld, G., P. K. George, J. Miller, P. Reilly, and J. Witztum. 1979. Apolipoprotein C-II and C-III levels in hyperlipoproteinemia. Metabolism. 28: 1001-1010.
3. Fredenrich, A., L-M. Giroux, M. Tremblay, L. Krimbou, J. Davignon, and J. S. Cohn. 1997. Plasma lipoprotein distribution of apoC-III in normolipidemic and hypertriglyceridemic subjects: comparison of the apoC-III to apoE ratio in different lipoprotein fractions. J. Lipid Res. 38: 1421-1432.
4. Curry, M. D., W. J. McConathy, J. D. Fesmire, and P. Alaupovic. 1980. Quantitative determination of human apolipoprotein C-III by electroimmunoassay. Biochim. Biophys. Acta. 617: 503-513.
5. Dammerman, M., L. A. Sandkuijl, J. L. Halaas, W. Chung, and J. L. Breslow. 1993. An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3′ untranslated region polymorphisms. Proc. Natl. Acad. Sci. USA. 90: 4562-4566.
6. Surguchov, A. P., G. P. Page, L. Smith, W. Patsch, and E. Boerwinkle. 1996. Polymorphic markers in apolipoprotein C-III gene flanking regions and hypertiglyceridemia. Arterioscler. Thromb. Vasc. Biol. 16: 941-947.
7. Ribalta, J., A. E. La Ville, J. C. Vallvé, S. Humphries, P. R. Turner, and L. Masana. 1997. A variation in the apolipoprotein C-III gene is associated with an increased number of circulating VLDL and IDL particles in familial combined hyperlipidemia. J. Lipid Res. 38: 1061-1069.
8. Forte, T. M., A. V. Nichols, R. M. Krauss, and R. A. Norum. 1984. Familial apolipoprotein AI and apolipoprotein CIII deficiency. Subclass distribution, composition, and morphology of lipoproteins in a disorder associated with premature atherosclerosis. J. Clin. Invest. 74: 1601-1613.
9. 58→Glu). Identification of an apolipoprotein C-III variant in a family with hyperalphalipoproteinemia. J. Clin. Invest. 87: 1724-1731.
10. Ito, Y., N. Azrolan, A. O'Connell, A. Walsh, and J. L. Breslow. 1990. Hypertriglyceridemia as a result of human apoCIII gene expression in transgenic mice. Science. 249: 790-793.
11. Maeda, N., H. Li, D. Lee, P. Oliver, S. H. Quarfordt, and J. Osada. 1994. Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia. J. Biol. Chem. 269: 23610-23616.
12. Brown, W. V., and M. L. Baginsky. 1972. Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein. Biochim. Biophys. Acta. 46: 375-382.
13. Van Barlingen, H. H. J. J., H. de Jong, D. W. Erkelens, and T. W. A. de Bruin. 1996. Lipoprotein lipase-enhanced binding of human triglyceride-rich lipoproteins to heparan sulfate: modulation by apolipoprotein E and apolipoprotein C. J. Lipid Res. 37: 754-763.
14. Windler, E., and R. J. Havel. 1985. Inhibitory effects of C apolipoproteins from rats and humans on the uptake of triglyceride-rich lipoproteins and their remnants by the perfused rat liver. J. Lipid Res. 26: 556-563.
15. Clavey, V., S. Lestavel-Delattre, C. Copin, J. M. Bard, and J. C. Fruchart. 1995. Modulation of lipoprotein B binding to the LDL receptor by exogenous lipids and apolipoproteins CI, CII, CIII and E. Arterioscler. Thromb. Vasc. Biol. 15: 963-971.
16. Mann, C. J., A. A. Troussard, F. T. Yen, N. Hannouche, J. Najib, J. C. Fruchart, V. Lotteau, P. Andre, and B. E. Bihain. 1997. Inhibitory effects of specific apolipoprotein C-III isoforms on the binding of triglyceride-rich lipoproteins to the lipolysis-stimulated receptor. J. Biol. Chem. 272: 31348-31354.
17. Ebara, T., R. Ramakrishnan, G. Steiner, and N. S. Shachter. 1997. Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E. J. Clin. Invest. 99: 2672-2681.
18. Weisgraber, K. H., R. W. Mahley, R. C. Kowal, J. Herz, J. L. Goldstein, and M. S. Brown. 1990. Apolipoprotein C-I modulates the interaction of apolipoprotein E with β-migrating very low density lipoproteins (β-VLDL) and inhibits binding of β-VLDL to low density lipoprotein receptor-related protein. J. Biol. Chem. 265: 22453-22459.
19. Weisgraber, K. H. 1994. Apolipoprotein E: structure-function relationships. Adv. Prot. Chem. 45: 249-302.
20. Blum, C. B., L. Aron, and R. Sciacca. 1980. Radioimmunoassay studies of human apolipoprotein E. J. Clin. Invest. 66: 1240-1250.
21. Havel, R. J., L. Kotite, J-L. Vigne, J. P. Kane, P. Tun, N. Phillips, and G. C. Chen. 1980. Radioimmunoassay of human arginine-rich apolipoprotein, apoprotein E. J. Clin. Invest. 66: 1351-1362.
22. Cohn, J. S., M. Tremblay, M. Amiot, D. Bouthillier, M. Roy, J. Genest, Jr., and J. Davignon. 1996. Plasma concentration of apolipoprotein E in intermediate-sized remnant-like lipoproteins in normolipidemic and hyperlipidemic subjects. Arterioscler. Thromb. Vasc. Biol. 16: 149-159.
23. Mahley, R. W., and Y. Huang. 1999. Apolipoprotein E: from atherosclerosis to Alzheimer's disease and beyond. Curr. Opin. Lipidol. 10: 207-217.
24. Mahley, R. W., and S.C. Rall, Jr. 1989. Type III hyperlipoproteinemia (dysbeta-lipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism. In The Metabolic Basis of Inherited Disease. C. R. Scriver, A. L. Beaudet, W. S. Sly, and D. Valle, editors. McGraw-Hill Publishing Co., New York, NY. 1195-1213.
25. 2, and VLDL-apolipoprotein B in normal and hyperlipoproteinemic subjects. J. Lipid Res. 22: 1235-1246.
26. 2 and VLDL-B in human subjects consuming high carbohydrate diets. Metabolism. 31: 493-498.
27. Bukberg, P. R., N-A. Le, H. N. Ginsberg, J. G. Gibson, A. Rubinstein, and W. V. Brown. 1985. Evidence for non-equilibrating pools of apolipoprotein C-III in plasma lipoproteins. J. Lipid Res. 26: 1047-1057.
28. Malmendier, C. L., J. F. Lontie, C. A. Grutman, and C. Delcroix. 1988. Metabolism of apolipoprotein C-III in normolipemic human subjects. Atherosclerosis. 69: 51-59.
29. Malmendier, C. L., J. F. Lontie, C. Delcroix, D. Y. Dubois, T. Magot, and L. De Roy. 1989. Apolipoproteins C-II and C-III metabolism in hypertriglyceridemic patients. Effects of a drastic triglyceride reduction by combined diet restriction and fenofibrate administration. Atherosclerosis. 77: 139-149.
30. Gregg, R. E., L. A. Zech, E. J. Schaefer, and H. B. Brewer, Jr. 1981. Type III hyperlipoproteinemia: defective metabolism of an abnormal apolipoprotein E. Science. 211: 584-586.
31. Gregg, R. E., L. A. Zech, E. J. Schaefer, and H. B. Brewer, Jr. 1984. Apolipoprotein E metabolism in normolipidemic human subjects. J. Lipid Res. 25: 1167-1176.
32. Gregg, R. E., L. A. Zech, E. J. Schaefer, D. Stark, D. Wilson, and H. B. Brewer, Jr. 1986. Abnormal in vivo metabolism of apolipoprotein E4 in humans. J. Clin. Invest. 78: 815-821.
33. Schaefer, E. J., R. E. Gregg, G. Ghiselli, T. M. Forte, J. M. Ordovas, L. A. Zech, and H. B. Brewer, Jr. 1986. Familial apolipoprotein E deficiency. J. Clin. Invest. 78: 1-14.
34. Ghiselli, G., Y. Beigel, M. Soma, and A. M. Gotto, Jr. 1986. Plasma catabolisin of human apolipoprotein E isoproteins: lack of conversion of the doubly sialilated form to the asialo form in plasma. Metabolism. 35: 399-403.
35. Millar, J. S., A. H. Lichtenstein, G. G. Dolnikowski, J. M. Ordovas, and E. J. Schaefer. 1998. Proposal of a multicompartmental model for use in the study of apolipoprotein E metabolism. Metabolism. 47: 922-928.
36. Davignon, J., J. Dallongeville, G. Roederer, M. Roy, J. C. Fruchart, A. M. Kessling, D. Bouthillier, and S. Lussier-Cacan. 1991. A phenocopy of the type III dyslipoproteinemia occuring in a candidate family for a putative apoE receptor defect. Ann. Med. 23: 161-167.
37. Cohn, J. S., D. A. Wagner, S. D. Cohn, J. S. Millar, and E. J. Schaefer. 1990. Measurement of very low density and low density lipoprotein apolipoprotein (apo) B-100 and high density lipoprotein apo A-I production in human subjects using deuterated leucine. Effect of fasting and feeding. J. Clin. Invest. 85: 804-811.
38. Batal, R., M. Tremblay, L. Krimbou, O. Mamer, J. Davignon, J. Genest, Jr., and J. S. Cohn. 1998. Familial HDL deficiency characterised by hypercatabolism of mature apoA-I but not proapoA-I. Arterioscler. Thromb. Vasc. Biol. 18: 655-664.
39. Albers, J. J., M. S. Lodge, and L. K. Curtiss. 1989. Evaluation of a monoclonal antibody-based enzyme-linked immunosorbent assay as a candidate reference method for the measurement of apolipoprotein B-100. J. Lipid Res. 30: 1445-1458.
40. Cobelli, C., G. Toffolo, and D. Foster. 1992. Tracer-to-tracee ratio for analysis of stable isotope tracer data: link with radioactive kinetic formalism. Am. J. Physiol. 262: E968-E975.
41. Riches, F. M., G. F. Watts, F. M. van Bockxmeer, J. Hua, S. Song, S. E. Humphries, and P. J. Talmud. 1998. Apolipoprotein B signal peptide and apolipoprotein E genotypes as determinants of the hepatic secretion of VLDL apoB in obese men. J. Lipid Res. 39: 1752-1758.
42. Chen, M., J. L. Breslow, W. Li, and T. Leff. 1994. Transcriptional regulation of the apoC-III gene by insulin in diabetic mice: correlation with changes in plasma triglyceride levels. J. Lipid Res. 35: 1918-1924.
43. Staels, B., N. Vu-Dac, V. A. Kosykh, R. Saladin, J. C. Fruchart, J. Dallongeville, and J. Auwerx. 1995. Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. J. Clin. Invest. 95: 705-712.
44. Vu-Dac, N., P. Gervois, I. P. Torra, J-C. Fruchart, V. Kosykh, T. Kooistra, H. M. G. Princen, J. Dallongeville, and B. Staels. 1998. Retinoids increase human apoC-III expression at the transcriptional level via the retinoid X receptor. Contribution to the hypertriglyceridemic action of retinoids. J. Clin. Invest. 102: 625-632.
45. Tornoci, L., C. A. Scheraldi, X. Li, H. Ide, I. J. Goldberg, and N-A. Le. 1993. Abnormal activation of lipoprotein lipase by non-equilibrating apoC-II: further evidence for the presence of non-equilibrating pools of apolipoproteins C-II and C-III in plasma lipoproteins. J. Lipid Res. 34: 1793-1803.
46. Rubinstein, A., J. C. Gibson, H. N. Ginsberg, and W. V. Brown. 1986. In vitro metabolism of apolipoprotein F. Biochim. Biophys. Acta. 879: 355-361.
47. Blum, C. B. 1982. Dynamics of apolipoprotein E metabolism in humans. J. Lipids Res. 23: 1308-1316.
48. Rubinstein, A., J. C. Gibson, J. R. Paterniti, Jr., G. Kakis, A. Little, H. N. Ginsberg, and W. V. Blown. 1985. Effect of heparin-induced lipolysis on the distribution of apolipoprotein E among lipoprotein subclasses. Studies with patients deficient in hepatic triglyceride lipase and lipoprotein lipase. J. Clin. Invest. 75: 710-721.
49. Noel, S-P., and D. Rubinstein. 1971. Secretion of apolipoproteins in very low density and high density lipoproteins by perfused rat liver. J. Lipid Res. 15: 301-308.
50. Hamilton, R. L., M. C. Williams, C. J. Fielding, and R. J. Havel. 1976. Discoidal bilayer structure of nascent high density lipoproteins from perfused rat liver. J. Clin. Invest. 58: 667-680.
51. Hamilton, R. L., J. S. Wong, L. S. S. Guo, S. Krisnas, and R. J. Havel. 1990. Apolipoprotein E localization in rat hepatocytes by immunogold labeling of cryothin sections. J. Lipid Res. 31: 1589-1603.
52. Fazio, S., Z. Yao, B. J. McCarthy, and S. C. Rall, Jr. 1992. Synthesis and secretion of apolipoprotein E occur independently of synthesis and secretion of apolipoprotein B-containing lipoproteins in HepG2 cells. J. Biol. Chem. 267: 6941-6945.
53. Hamilton, R. L., A. Moorehouse, and R. J. Havel. 1991. Isolation and properties of nascent lipoproteins from highly purified rat hepatocytic Golgi fractions. J. Lipid Res. 32: 529-543.
54. Fazio, S., and Z. Yao. 1995. The enhanced association of apolipoprotein E with apolipoprotein B-containing lipoproteins in serum-stimulated hepatocytes occurs intracellularly. Arterioscler. Thromb. Vasc. Biol. 15: 593-600.
55. Rall, S. C., Jr., K. H. Weisgraber, T. L. Innerarity, R. W. Mahley, and G. Assmann. 1983. Identical structural and receptor binding defects in apolipoprotein E2 in hypo-, normo-, and hypercholesterolemic dysbetalipoproteinemia. J. Clin. Invest. 71: 1023-1031.
56. Hopkins, P. N., L. L. Wu, M. C. Schumacher, M. Emi, R. M. Hegele, S. C. Hunt, J-M Lalouel, and R. R. Williams. 1991. Type III dyslipoproteinemia in patients heterozygous for familial hypercholesterolemia and apolipoprotein E2. Evidence for a gene-gene interaction. Arterioscler. Thromb. 11: 1137-1146.
57. Groenewegen, W. A., E. S. Krul, M. R. Averna, J. Pulai, and G. Schonfeld. 1994. Dysbetalipoproteinemia in a kindred with hypobetalipoproteinemia due to mutations in the genes for apoB (apoB-70.5) and apoE (apoE2). Arterioscler. Thromb. 14: 1695-1704.
58. Chait, A., W. R. Hazzard, J. J. Albers, R. P. Kushwaha, and J. D. Brunzell. 1978. Impaired very low density lipoprotein and triglyceride removal in broad beta disease: comparison with endogenous hypertriglyceridemia. Metabolism. 27: 1055-1066.
59. Stalenhoef, A. F. H., M. J. Malloy, J. P. Kane, and R. J. Havel. 1986. Metabolism of apolipoproteins B-48 and B-100 of triglyceride-rich lipoproteins in patients with familial dysbetalipoproteinemia. J. Clin. Invest. 78: 722-728.
60. 164→Glu). J. Clin. Invest. 96: 1100-1107.